Literature DB >> 9950753

Using thymus anatomy to dissect T cell repertoire selection.

T M Laufer1, L H Glimcher, D Lo.   

Abstract

The thymic development of CD4(+) T cells incorporates the opposing processes of positive and negative selection to produce mature lymphocytes which respond to foreign peptides in the context of self-major histocompatibility complex class II molecules. Here, we present a model in which these events occur in two temporally and anatomically distinct steps. We propose that an initial positive selection step is mediated exclusively by thymic cortical epithelium. Subsequently, all those thymocytes which have been positively selected will interact with medullary epithelium and bone marrow-derived cells. Those thymocytes reacting with excess affinity or avidity to these antigen presenting cells will be negatively selected. Although acknowledging the importance of differential signalling to the developing thymocyte, we will emphasize the centrality of the phenotype of the tissues which comprise the thymus. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9950753     DOI: 10.1006/smim.1998.9997

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  13 in total

Review 1.  The thymus and negative selection.

Authors:  H Kishimoto; J Sprent
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

2.  BCL10 expression in normal and neoplastic lymphoid tissue. Nuclear localization in MALT lymphoma.

Authors:  H Ye; A Dogan; L Karran; T G Willis; L Chen; I Wlodarska; M J Dyer; P G Isaacson; M Q Du
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

3.  Interferons mediate terminal differentiation of human cortical thymic epithelial cells.

Authors:  Pierre-Olivier Vidalain; David Laine; Yona Zaffran; Olga Azocar; Christine Servet-Delprat; T Fabian Wild; Chantal Rabourdin-Combe; Hélène Valentin
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

4.  Immune ontogeny and engraftment receptivity in the sheep fetus.

Authors:  Jessica L Skopal-Chase; John S Pixley; Alireza Torabi; Mihai C Cenariu; Anupama Bhat; David S Thain; Nicole M Frederick; Daria M Groza; Esmail D Zanjani
Journal:  Fetal Diagn Ther       Date:  2009-02-25       Impact factor: 2.587

5.  Foxn1 is required to maintain the postnatal thymic microenvironment in a dosage-sensitive manner.

Authors:  Lizhen Chen; Shiyun Xiao; Nancy R Manley
Journal:  Blood       Date:  2008-10-31       Impact factor: 22.113

6.  Immune tolerance. Group 3 innate lymphoid cells mediate intestinal selection of commensal bacteria-specific CD4⁺ T cells.

Authors:  Matthew R Hepworth; Thomas C Fung; Samuel H Masur; Judith R Kelsen; Fiona M McConnell; Juan Dubrot; David R Withers; Stephanie Hugues; Michael A Farrar; Walter Reith; Gérard Eberl; Robert N Baldassano; Terri M Laufer; Charles O Elson; Gregory F Sonnenberg
Journal:  Science       Date:  2015-04-23       Impact factor: 47.728

7.  Rapid reconstitution of antibody responses following transplantation of purified allogeneic hematopoietic stem cells.

Authors:  Jessica A Linderman; Judith A Shizuru
Journal:  J Immunol       Date:  2011-02-28       Impact factor: 5.422

8.  Cathepsin V is involved in the degradation of invariant chain in human thymus and is overexpressed in myasthenia gravis.

Authors:  Eva Tolosa; Weijie Li; Yoshiyuki Yasuda; Wolfgang Wienhold; Lisa K Denzin; Alfred Lautwein; Christoph Driessen; Petra Schnorrer; Ekkehard Weber; Stefan Stevanovic; Raffael Kurek; Arthur Melms; Dieter Bromme
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

9.  Thymic epithelial requirement for γδ T cell development revealed in the cell ablation transgenic system with TSCOT promoter.

Authors:  Gwanghee Lee; Ki Yeon Kim; Cheong-Hee Chang; Moon Gyo Kim
Journal:  Mol Cells       Date:  2012-11-15       Impact factor: 5.034

10.  Tolerance to self: which cells kill?

Authors:  Terri M Laufer
Journal:  PLoS Biol       Date:  2008-09-30       Impact factor: 8.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.